サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1728071

多がんスクリーニング市場- 世界の産業規模、シェア、動向、機会、予測、検査タイプ別、技術別、サンプル別、方法別、がんタイプ別、用途別、エンドユーザー別、地域別、競合別、2020-2030年

Multicancer Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Technology, By Sample, By Method, By Cancer Type, By Application, By End User, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 189 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

多がんスクリーニング市場- 世界の産業規模、シェア、動向、機会、予測、検査タイプ別、技術別、サンプル別、方法別、がんタイプ別、用途別、エンドユーザー別、地域別、競合別、2020-2030年
出版日: 2025年05月16日
発行: TechSci Research
ページ情報: 英文 189 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

多がんスクリーニングの世界市場は、2024年に14億1,000万米ドルと評価され、予測期間中のCAGRは15.12％を記録し、2030年には32億9,000万米ドルに達すると予測されています。

がんの早期発見に対する意識の高まり、様々ながん種の罹患率の増加、ゲノム解析の技術進歩に支えられ、市場は急速に拡大しています。ヘルスケアシステムは、リキッドバイオプシー、次世代シーケンシング（NGS）、複数のがんを同時にスクリーニングするAI統合バイオインフォマティクスプラットフォームなど、非侵襲的な早期発見法への投資を増やしています。

市場概要
予測期間 2026-2030
市場規模：2024年 14億1,000万米ドル
市場規模：2030年 32億9,000万米ドル
CAGR：2025年～2030年 15.12%
急成長セグメント 消化器
最大市場 北米

Cancer Moonshotプログラムやその他の国際的な資金提供プロジェクトなど、政府が支援するイニシアチブが研究と商業展開をさらに加速させています。診断薬開発企業と学術機関との戦略的パートナーシップは、強固な臨床検証と幅広い採用を促進しています。こうした取り組みと、予防医療や集団レベルのスクリーニング戦略へのシフトが相まって、先進国市場でも新興国市場でも多発がん早期発見（MCED）検査の勢いが増しています。

主な市場促進要因

慢性疾患の有病率の増加

主な市場課題

標準化と臨床検証の欠如

主要市場動向

リキッドバイオプシーとゲノム技術の統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の多がんスクリーニング市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 検査の種類別（臨床検査（LDT）、体外診断（IVD））
    • 技術別（次世代シーケンシング（NGS）、ポリメラーゼ連鎖反応（PCR）、免疫組織化学（IHC）、蛍光in-situハイブリダイゼーション（FISH）、その他）
    • サンプル別（組織、血液、唾液、口腔スワブ、その他）
    • 方法別（DNA、RNA、タンパク質）
    • がんの種類別（乳がん、婦人科がん、消化器がん、内分泌がん、泌尿生殖器がん、皮膚がん、脳神経系がん、肉腫、造血悪性腫瘍、肺がん、頭頸部がん、その他のがん）
    • 用途別（臨床、調査）
    • エンドユーザー別（病院、診断・臨床検査室、学術調査機関、その他）
    • 企業別（2024）
    • 地域別
  • 市場マップ

第6章 北米の多がんスクリーニング市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州の多がんスクリーニング市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の多がんスクリーニング市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米の多がんスクリーニング市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの多がんスクリーニング市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Agilent Technologies, Inc.
  • Atara Biotherapeutics, Inc.
  • Burning Rock Biotech Limited
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics, Inc.
  • Genecast Biotechnology Co., Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Konica Minolta, Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 15592

The Global Multicancer Screening Market was valued at USD 1.41 billion in 2024 and is projected to reach USD 3.29 billion by 2030, registering a CAGR of 15.12% during the forecast period. The market is expanding rapidly, supported by heightened awareness around early cancer detection, growing incidence rates of various cancer types, and technological advancements in genomic analysis. Healthcare systems are increasingly investing in non-invasive early detection methods, including liquid biopsy, next-generation sequencing (NGS), and AI-integrated bioinformatics platforms that facilitate screening for multiple cancers simultaneously.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.41 Billion
Market Size 2030USD 3.29 Billion
CAGR 2025-203015.12%
Fastest Growing SegmentGastrointestinal
Largest MarketNorth America

Government-backed initiatives, such as the Cancer Moonshot program and other international funding projects, are further accelerating research and commercial deployment. Strategic partnerships between diagnostic developers and academic institutions are fostering robust clinical validation and broader adoption. These efforts, combined with the shift toward preventive care and population-level screening strategies, are driving strong momentum for multicancer early detection (MCED) tests in both developed and emerging markets.

Key Market Drivers

Increasing Prevalence of Chronic Diseases

The growing global burden of cancer continues to be a major driver for the multicancer screening market. Rising incidences of cancer types such as breast, lung, colorectal, prostate, and stomach cancer are fueling the demand for comprehensive screening solutions. For example, in 2023 alone, approximately 300,590 new cases of breast cancer were diagnosed in the U.S. According to the World Health Organization, global cancer data from 2020 showed 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, and over 1 million cases each for colon, prostate, skin (non-melanoma), and stomach cancers.

Countries like Denmark, Ireland, and Australia continue to record some of the highest cancer incidence rates globally, indicating a pressing need for early, accurate, and efficient detection methods. Multicancer screening platforms offer the potential to identify a wide array of cancers at earlier stages, improving prognosis and reducing mortality rates. As cancer rates rise, especially in aging and urbanizing populations, the need for reliable MCED solutions will continue to grow, reinforcing market demand.

Key Market Challenges

Lack of Standardization and Clinical Validation

One of the primary challenges faced by the multicancer screening market is the lack of harmonized standards and comprehensive clinical validation for newer screening tests. Despite significant innovation, the absence of universal testing protocols and diagnostic benchmarks across geographies leads to inconsistent results, limiting test reliability. Without standardized procedures, healthcare providers may remain cautious in adopting multicancer screening technologies.

Moreover, many MCED platforms lack validation through large-scale clinical trials, which are essential for establishing clinical efficacy, sensitivity, and specificity. Regulatory agencies demand substantial evidence before approving these tools for widespread use. Without such validation, uncertainty persists regarding the accuracy and practical application of these tests in real-world settings. This slows down market adoption and hinders regulatory acceptance, particularly in diverse population groups with varying risk profiles.

Key Market Trends

Integration of Liquid Biopsy and Genomic Technologies

A prominent trend shaping the multicancer screening landscape is the convergence of liquid biopsy and advanced genomic technologies. Liquid biopsy methods analyze biomarkers such as circulating tumor DNA (ctDNA), RNA, and exosomes from blood or other fluids, offering a minimally invasive approach to early cancer detection. These techniques allow for cancer identification even before symptoms emerge, and they support ongoing disease monitoring and treatment assessment.

When paired with high-throughput genomic tools such as next-generation sequencing (NGS), the accuracy and scope of liquid biopsy expand significantly. NGS enables comprehensive mutation analysis and enhances the detection of multiple cancer types from a single sample. As these technologies become more cost-effective and refined, their adoption is increasing for large-scale, multi-cancer screening. This integration improves test efficiency, reduces patient burden, and supports broader implementation of population-wide cancer detection programs.

Key Market Players

  • Agilent Technologies, Inc.
  • Atara Biotherapeutics, Inc.
  • Burning Rock Biotech Limited
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics, Inc.
  • Genecast Biotechnology Co., Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Konica Minolta, Inc.

Report Scope

In this report, the Global Multicancer Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multicancer Screening Market, By Test Type:

  • Laboratory Developed Tests (LDTs)
  • In-Vitro Diagnostics (IVDs)

Multicancer Screening Market, By Technology:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Fluorescence In-Situ Hybridization (FISH)
  • Others

Multicancer Screening Market, By Sample:

  • Tissue
  • Blood
  • Saliva and Buccal Swab
  • Others

Multicancer Screening Market, By Method:

  • DNA
  • RNA
  • Proteins

Multicancer Screening Market, By Cancer Type:

  • Breast and Gynecologic
  • Gastrointestinal
  • Endocrine
  • Genitourinary
  • Skin
  • Brain/Nervous System
  • Sarcoma
  • Hematological Malignancies
  • Lung
  • Head and Neck
  • Other Cancer Types

Multicancer Screening Market, By Application:

  • Clinical
  • Research

Multicancer Screening Market, By End User:

  • Hospitals
  • Diagnostic and Clinical Laboratories
  • Academic Research Institutions
  • Others

Multicancer Screening Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multicancer Screening Market.

Available Customizations

Global Multicancer Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Multicancer Screening Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs))
    • 5.2.2. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Others)
    • 5.2.3. By Sample (Tissue, Blood, Saliva and Buccal Swab, Others)
    • 5.2.4. By Method (DNA, RNA, Proteins)
    • 5.2.5. By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, Other Cancer Types)
    • 5.2.6. By Application (Clinical, Research)
    • 5.2.7. By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, Others)
    • 5.2.8. By Company (2024)
    • 5.2.9. By Region
  • 5.3. Market Map

6. North America Multicancer Screening Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Technology
    • 6.2.3. By Sample
    • 6.2.4. By Method
    • 6.2.5. By Cancer Type
    • 6.2.6. By Application
    • 6.2.7. By End User
    • 6.2.8. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Multicancer Screening Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Sample
        • 6.3.1.2.4. By Method
        • 6.3.1.2.5. By Cancer Type
        • 6.3.1.2.6. By Application
        • 6.3.1.2.7. By End User
    • 6.3.2. Mexico Multicancer Screening Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Sample
        • 6.3.2.2.4. By Method
        • 6.3.2.2.5. By Cancer Type
        • 6.3.2.2.6. By Application
        • 6.3.2.2.7. By End User
    • 6.3.3. Canada Multicancer Screening Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Sample
        • 6.3.3.2.4. By Method
        • 6.3.3.2.5. By Cancer Type
        • 6.3.3.2.6. By Application
        • 6.3.3.2.7. By End User

7. Europe Multicancer Screening Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Technology
    • 7.2.3. By Sample
    • 7.2.4. By Method
    • 7.2.5. By Cancer Type
    • 7.2.6. By Application
    • 7.2.7. By End User
    • 7.2.8. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Multicancer Screening Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Sample
        • 7.3.1.2.4. By Method
        • 7.3.1.2.5. By Cancer Type
        • 7.3.1.2.6. By Application
        • 7.3.1.2.7. By End User
    • 7.3.2. Germany Multicancer Screening Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Sample
        • 7.3.2.2.4. By Method
        • 7.3.2.2.5. By Cancer Type
        • 7.3.2.2.6. By Application
        • 7.3.2.2.7. By End User
    • 7.3.3. United Kingdom Multicancer Screening Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Sample
        • 7.3.3.2.4. By Method
        • 7.3.3.2.5. By Cancer Type
        • 7.3.3.2.6. By Application
        • 7.3.3.2.7. By End User
    • 7.3.4. Italy Multicancer Screening Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Sample
        • 7.3.4.2.4. By Method
        • 7.3.4.2.5. By Cancer Type
        • 7.3.4.2.6. By Application
        • 7.3.4.2.7. By End User
    • 7.3.5. Spain Multicancer Screening Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Sample
        • 7.3.5.2.4. By Method
        • 7.3.5.2.5. By Cancer Type
        • 7.3.5.2.6. By Application
        • 7.3.5.2.7. By End User

8. Asia-Pacific Multicancer Screening Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Technology
    • 8.2.3. By Sample
    • 8.2.4. By Method
    • 8.2.5. By Cancer Type
    • 8.2.6. By Application
    • 8.2.7. By End User
    • 8.2.8. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Multicancer Screening Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Sample
        • 8.3.1.2.4. By Method
        • 8.3.1.2.5. By Cancer Type
        • 8.3.1.2.6. By Application
        • 8.3.1.2.7. By End User
    • 8.3.2. India Multicancer Screening Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Sample
        • 8.3.2.2.4. By Method
        • 8.3.2.2.5. By Cancer Type
        • 8.3.2.2.6. By Application
        • 8.3.2.2.7. By End User
    • 8.3.3. South Korea Multicancer Screening Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Sample
        • 8.3.3.2.4. By Method
        • 8.3.3.2.5. By Cancer Type
        • 8.3.3.2.6. By Application
        • 8.3.3.2.7. By End User
    • 8.3.4. Japan Multicancer Screening Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Sample
        • 8.3.4.2.4. By Method
        • 8.3.4.2.5. By Cancer Type
        • 8.3.4.2.6. By Application
        • 8.3.4.2.7. By End User
    • 8.3.5. Australia Multicancer Screening Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Sample
        • 8.3.5.2.4. By Method
        • 8.3.5.2.5. By Cancer Type
        • 8.3.5.2.6. By Application
        • 8.3.5.2.7. By End User

9. South America Multicancer Screening Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Technology
    • 9.2.3. By Sample
    • 9.2.4. By Method
    • 9.2.5. By Cancer Type
    • 9.2.6. By Application
    • 9.2.7. By End User
    • 9.2.8. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Multicancer Screening Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Sample
        • 9.3.1.2.4. By Method
        • 9.3.1.2.5. By Cancer Type
        • 9.3.1.2.6. By Application
        • 9.3.1.2.7. By End User
    • 9.3.2. Argentina Multicancer Screening Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Sample
        • 9.3.2.2.4. By Method
        • 9.3.2.2.5. By Cancer Type
        • 9.3.2.2.6. By Application
        • 9.3.2.2.7. By End User
    • 9.3.3. Colombia Multicancer Screening Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Sample
        • 9.3.3.2.4. By Method
        • 9.3.3.2.5. By Cancer Type
        • 9.3.3.2.6. By Application
        • 9.3.3.2.7. By End User

10. Middle East and Africa Multicancer Screening Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Technology
    • 10.2.3. By Sample
    • 10.2.4. By Method
    • 10.2.5. By Cancer Type
    • 10.2.6. By Application
    • 10.2.7. By End User
    • 10.2.8. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Multicancer Screening Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Sample
        • 10.3.1.2.4. By Method
        • 10.3.1.2.5. By Cancer Type
        • 10.3.1.2.6. By Application
        • 10.3.1.2.7. By End User
    • 10.3.2. Saudi Arabia Multicancer Screening Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Sample
        • 10.3.2.2.4. By Method
        • 10.3.2.2.5. By Cancer Type
        • 10.3.2.2.6. By Application
        • 10.3.2.2.7. By End User
    • 10.3.3. UAE Multicancer Screening Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Sample
        • 10.3.3.2.4. By Method
        • 10.3.3.2.5. By Cancer Type
        • 10.3.3.2.6. By Application
        • 10.3.3.2.7. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Agilent Technologies, Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Atara Biotherapeutics, Inc.
  • 14.3. Burning Rock Biotech Limited
  • 14.4. Exact Sciences Corporation
  • 14.5. F. Hoffmann-La Roche Ltd.
  • 14.6. Fulgent Genetics, Inc.
  • 14.7. Genecast Biotechnology Co., Ltd.
  • 14.8. Guardant Health, Inc.
  • 14.9. Illumina, Inc.
  • 14.10. Konica Minolta, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer